Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Planning Treatment for Oesophago-gastric Cancer: a Randomised Maintenance Therapy Trial
Brief Summary: To evaluate the efficacy of maintenance therapies following completion of standard first-line chemotherapy in patients with locally advanced or metastatic HER-2 positive or HER-2 negative oesophago-gastric adenocarcinomas.


Options:
A: Arm Label: 1- Docetaxel plus Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: oxaliplatin | Arm Label: 2- Docetaxel plus oxaliplatin plus cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: cetuximab, Drug: oxaliplatin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab
B: Arm Label: A1: Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm A2: Capecitabine Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine | Arm Label: Arm A3: MEDI4736 (Durvalumab); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 (Durvalumab) | Arm Label: Arm B1: Trastuzumab Maintenance; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trastuzumab | Arm Label: Arm A4: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Arm A5: Capecitabine and Ramucirumab; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Drug: Ramucirumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm A2: Capecitabine Maintenance, Arm A5: Capecitabine and Ramucirumab | Intervention Type: DRUG; Name: MEDI4736 (Durvalumab); Assigned to Arm(s): Arm A3: MEDI4736 (Durvalumab) | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Arm B1: Trastuzumab Maintenance | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Arm A4: Rucaparib | Intervention Type: DRUG; Name: Ramucirumab; Assigned to Arm(s): Arm A5: Capecitabine and Ramucirumab
C: Arm Label: Everolimus + BSC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Best Supportive Care (BSC) | Arm Label: Placebo + BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus placebo, Drug: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + BSC | Intervention Type: DRUG; Name: Everolimus placebo; Assigned to Arm(s): Placebo + BSC | Intervention Type: DRUG; Name: Best Supportive Care (BSC); Assigned to Arm(s): Everolimus + BSC, Placebo + BSC
D: Arm Label: Standard taxane therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Taxane | Arm Label: trastuzumab emtansine 2.4 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Arm Label: trastuzumab emtansine 3.6 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Intervention Type: DRUG; Name: Taxane; Assigned to Arm(s): Standard taxane therapy | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 3.6 mg | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 2.4 mg

Answer: B